Your browser doesn't support javascript.
loading
Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report.
Ambadapoodi, Raghava S; Arnold, Forest W; Chariker, Julia H; Glynn, Alex; Lauer, William; Marimuthu, Subathra; Rouchka, Eric C; Smith, Melissa L; Wolf, Leslie A.
Afiliação
  • Ambadapoodi RS; Department of Neurology, University of Chicago Medical Center, Chicago, IL.
  • Arnold FW; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
  • Chariker JH; Neuroscience Training Department, University of Louisville, Louisville, KY.
  • Glynn A; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
  • Lauer W; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY.
  • Marimuthu S; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
  • Rouchka EC; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY.
  • Smith ML; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY.
  • Wolf LA; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
Res Sq ; 2023 Apr 04.
Article em En | MEDLINE | ID: mdl-37066424
ABSTRACT
A 44-year-old female patient with multiple sclerosis (MS) treated with ocrelizumab was hospitalized with SARS-CoV-2 pneumonia three times over the course of five months, eventually expiring. Viral sequencing of samples from her first and last admissions suggests a single persistent SARS-CoV-2 infection. We hypothesize that her immunocompromised state, due to MS treatment with an immunosuppressive monoclonal antibody, prevented her from achieving viral clearance.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article